Inotiv
Inotiv is a pharmaceutical development company that specializes in nonclinical and analytical drug discovery and development services for the pharmaceutical, chemical, and medical device sectors. The company operates through two primary segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DSA segment provides comprehensive support for the discovery and nonclinical development of small molecule drug candidates, biotherapeutics, and biomedical devices, catering to the needs of researchers and clinicians. Meanwhile, the RMS segment offers a diverse range of small and large research models, facilitating basic research and drug development processes. Inotiv's services encompass biopharmaceutical analytics, reproductive toxicology, medical device testing, drug metabolism and pharmacokinetics (DMPK), and consulting, positioning the company as a key player in the drug development landscape.
4 past transactions
Protypia
Acquisition in 2022
Protypia is an emerging bioanalytical company specializing in protein and peptide analysis through advanced mass spectrometry techniques. The company provides a targeted proteomics platform that enables precise quantification of drug target systems within cells, tissue models, and human tissues. By integrating protein-level pharmacology and pathology, Protypia supports various therapeutic areas and modalities throughout the drug discovery and clinical development processes. This approach allows clients to effectively analyze drug targets and identify critical protein features, enhancing their research and development efforts.
Histion
Acquisition in 2022
Histion is a company that provides scientific and technical expertise, focusing on preclinical services for the Medical Device, Pharmaceutical, and Biotechnology industries. It specializes in histopathology and evaluations of medical devices, offering laboratory services for a diverse array of product types, including novel biomaterials, drugs, biologics, and various delivery devices such as cutaneous, percutaneous, implantable, injectable, and ingestible forms. Histion aims to support clients in their product development needs, facilitating advancements in clinical applications.
Envigo
Acquisition in 2021
Envigo is a provider of essential products and research services tailored for pharmaceutical, biotechnology, crop protection, and chemical companies, as well as universities and governmental organizations. The company specializes in early-stage non-clinical contract research services that include biological product research, contract breeding, custom antibody production, health monitoring, genetic testing, and surgical services. Envigo is dedicated to helping its clients realize the full potential of their research and products, contributing to advancements that enhance the lives of people and animals and promote environmental protection. With a focus on collaboration and customer service, Envigo aims to support researchers in achieving their goals in life sciences.
Plato Biopharma
Acquisition in 2021
Plato Biopharma is a global preclinical drug discovery Contract Research Organization (CRO) that specializes in conducting in vivo physiological and pharmacological studies across various therapeutic areas such as cardiovascular, renal, pulmonary, diabetes, and hepatic diseases. The company complements its core services with biochemical, biomarker, and histology analysis to provide comprehensive data for clients' drug development programs. Its platform aims to generate decision-enabling data through pathophysiological and pharmacological research, enabling the discovery of new treatments for life-threatening diseases in these therapeutic areas.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.